T-Cypher’s vision is to unlock an expansive target space to build a pipeline of novel, T-cell receptor (TCR)-based therapeutics. In realising this vision, the company’s focus is to discover novel TCRs against novel targets by deploying its next-generation, proprietary, target and TCR-discovery platforms.

T-Cypher was founded in 2021 based on exclusive technology licenses from The University of Oxford and is seed-funded with Oxford Science Enterprises as the majority shareholder. The company has attracted experienced leadership from leading companies covering computational biology, TCR discovery and preclinical development, cell therapy process engineering, gene engineering and immune oncology. T-Cypher CEO Thomas L. Andresen is a serial entrepreneur and co-founder of several life science companies at clinical and market stage. These include Boston’s Torque Therapeutics which went on to become Repertoire Immune Medicines, where he was the founding CSO.

T-Cypher holds exclusive IP on high-throughput technology that identifies and deeply characterises the link between T cell repertoires and disease-specific intracellular targets. In this manner they are able to quickly identify effective TCRs against panels of targets of interest for subsequent development into differentiated therapeutics.